Previous Close | 9.71 |
Open | 9.67 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 9.65 - 9.65 |
52 Week Range | 7.11 - 13.13 |
Volume | |
Avg. Volume | 2,474 |
Market Cap | 46.381M |
Beta (5Y Monthly) | -0.44 |
PE Ratio (TTM) | 68.93 |
EPS (TTM) | 0.14 |
Earnings Date | Mar 25, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Jan 05, 2018 |
1y Target Est | 23.25 |
Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients. Data from both studies demonstrate
The Premier Event for Cardiovascular Industry Leaders and Clinicians Oak Ridge, TN, April 15, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today it will be exhibiting at the MedAxiom CV Transforum Spring’24 Conference being held at the Atlanta Marriott Marquis in GA, from April 18-20, 2024. The CV Transforum conference, hosted by MedAxiom, an American College of Cardiology company, unites cardiovascular thought lead
450-Bed Hospital Purchases BVA-100™ Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology today announces the purchase of Daxor’s BVA-100™ at a 450-bed teaching hospital in the greater Chicago area. “Hospitals are utilizing our BVA diagnostic to save money by reducing length of stay while improving Hospital Readmissions Reduction Program (HRRP) quality metri